<b>PRISMA checklist for ‘Safety of remimazolam in comparison with midazolam for colonoscopy: A systematic review and meta-analysis</b>

This is the PRISMA checklist used to make an outline for our systematic review and meta-analysis. The checklist was mostly followed to include and highlight the important findings in our study.Purpose: Compare the safety profile between Remimazolam and Midazolam by screening for Treatment emergent adverse effectsMethodology: Two individual researchers used PubMed/MEDLINE and the Cochrane Library and searched for relevant randomized control trials up to July 17^th, 2023. MedRxiv and BioRxiv were also searched for preprints and other related articles. All significant studies were included using the relevant medical subject headings (Mesh terms). The used search strategy was: ((Remimazolam) OR (ONO 2745)) OR (ONO-2745)) OR ((CNS7056)) OR ((methyl 3-(8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo(1,2-a)(1,4)benzodiazepin-4-yl)propanoate)) AND ((Midazolam) OR (Midazolam Maleate)) OR ((Maleate, Midazolam)) OR (Dormicum)) OR (Versed)) OR (Midazolam Hydrochloride)) OR (Hydrochloride, Midazolam)) OR (Ro 21-3981)) AND ((Colonoscopy) OR (Colonoscopic Surgical Procedures)).本研究采用PRISMA清单（PRISMA checklist）作为系统综述与荟萃分析的研究框架，并严格遵循该清单以纳入研究并凸显本研究的关键发现。 研究目的：通过筛查治疗突发不良反应，比较瑞马唑仑（Remimazolam）与咪达唑仑（Midazolam）的安全性特征。 研究方法：由两名独立研究者检索PubMed/MEDLINE及Cochrane Library数据库，筛选截至2023年7月17日发表的相关随机对照试验；同时检索MedRxiv与BioRxiv预印本平台及其他相关文献。本研究采用医学主题词（Mesh术语）筛选合格研究，所用检索策略为：((Remimazolam) OR (ONO 2745)) OR (ONO-2745)) OR ((CNS7056)) OR ((methyl 3-(8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo(1,2-a)(1,4)benzodiazepin-4-yl)propanoate)) AND ((Midazolam) OR (Midazolam Maleate)) OR ((Maleate, Midazolam)) OR (Dormicum)) OR (Versed)) OR (Midazolam Hydrochloride)) OR (Hydrochloride, Midazolam)) OR (Ro 21-3981)) AND ((Colonoscopy) OR (Colonoscopic Surgical Procedures))。